Studies have shown that neoadjuvant PD-1 inhibitors alone for locally advanced HNSCC have relatively low MPR and pCR rates, whereas combining them with other therapies significantly improves these key efficacy metrics (12, 13, 24). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.